KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBT (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed EBT for 18 consecutive years, with -$92.3 million as the latest value for Q1 2026.

  • For Q1 2026, EBT rose 37.13% year-over-year to -$92.3 million; the TTM value through Mar 2026 reached $56.1 million, up 1725.38%, while the annual FY2025 figure was $1.6 million, 145.19% up from the prior year.
  • EBT hit -$92.3 million in Q1 2026 for Ionis Pharmaceuticals, down from $153.3 million in the prior quarter.
  • Across five years, EBT topped out at $353.7 million in Q4 2024 and bottomed at -$146.8 million in Q1 2025.
  • Average EBT over 5 years is -$40.2 million, with a median of -$77.4 million recorded in 2023.
  • Year-over-year, EBT plummeted 201.46% in 2023 and then skyrocketed 10179.03% in 2024.
  • Ionis Pharmaceuticals' EBT stood at -$44.3 million in 2022, then soared by 92.08% to -$3.5 million in 2023, then surged by 10179.03% to $353.7 million in 2024, then crashed by 56.67% to $153.3 million in 2025, then crashed by 160.23% to -$92.3 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$92.3 million, $153.3 million, and -$128.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.